(QGEN) Qiagen - Ratings and Ratios
Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0015002CX3
QGEN EPS (Earnings per Share)
QGEN Revenue
QGEN: Sample, Instruments, Assay, Genomics
Qiagen NV is a leading provider of molecular diagnostics and life sciences tools, offering a comprehensive range of products and services that enable the analysis of biological samples. The companys extensive portfolio includes sample preparation, DNA/RNA extraction, and PCR-based testing solutions, as well as bioinformatics and laboratory services. Qiagens products cater to various markets, including molecular diagnostics, academia, pharmaceuticals, and applied testing.
The companys diverse product offerings are designed to facilitate the discovery, development, and delivery of life sciences and molecular diagnostics solutions. Qiagens sample to insight solutions enable researchers and clinicians to extract valuable insights from biological samples, driving advancements in fields such as oncology, infectious diseases, and genetic disorders. With a strong presence in the global market, Qiagen serves a broad customer base, including top pharmaceutical companies, research institutions, and healthcare providers.
From a technical analysis perspective, Qiagens stock has shown a positive trend, with its 20-day SMA at $43.36 and 50-day SMA at $42.08, indicating a potential bullish signal. The stocks current price is $45.56, with an ATR of 0.85, representing a 1.87% daily volatility. Considering the companys fundamental data, including a market capitalization of $9.5 billion and a forward P/E ratio of 17.39, we can forecast a potential price target. Based on the convergence of technical and fundamental indicators, we predict that Qiagens stock may reach $50.00 within the next 6-12 months, driven by the companys continued innovation, expanding product portfolio, and growing demand for molecular diagnostics and life sciences tools.
Our forecast is supported by Qiagens improving financial performance, driven by its diversified revenue streams and strategic investments in emerging markets. The companys commitment to R&D and its expanding portfolio of innovative products are expected to drive growth and increase its market share. As the demand for molecular diagnostics and life sciences tools continues to rise, Qiagen is well-positioned to capitalize on this trend, driven by its strong brand, global presence, and comprehensive product offerings.
Additional Sources for QGEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
QGEN Stock Overview
Market Cap in USD | 10,403m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1996-06-28 |
QGEN Stock Ratings
Growth Rating | -21.0 |
Fundamental | -7.82 |
Dividend Rating | 3.10 |
Rel. Strength | 26.2 |
Analysts | 3.94 of 5 |
Fair Price Momentum | 46.02 USD |
Fair Price DCF | 43.53 USD |
QGEN Dividends
Dividend Yield 12m | 3.30% |
Yield on Cost 5y | 3.54% |
Annual Growth 5y | % |
Payout Consistency | 8.8% |
Payout Ratio | 65.1% |
QGEN Growth Ratios
Growth Correlation 3m | 91.2% |
Growth Correlation 12m | -12.8% |
Growth Correlation 5y | -75% |
CAGR 5y | 2.44% |
CAGR/Max DD 5y | 0.07 |
Sharpe Ratio 12m | -0.27 |
Alpha | 6.64 |
Beta | 0.563 |
Volatility | 17.86% |
Current Volume | 807.2k |
Average Volume 20d | 1237.6k |
As of July 01, 2025, the stock is trading at USD 48.06 with a total of 807,195 shares traded.
Over the past week, the price has changed by +2.89%, over one month by +7.04%, over three months by +19.70% and over the past year by +19.38%.
Neither. Based on ValueRay´s Fundamental Analyses, Qiagen is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.82 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QGEN is around 46.02 USD . This means that QGEN is currently overvalued and has a potential downside of -4.24%.
Qiagen has received a consensus analysts rating of 3.94. Therefor, it is recommend to buy QGEN.
- Strong Buy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, QGEN Qiagen will be worth about 51.3 in July 2026. The stock is currently trading at 48.06. This means that the stock has a potential upside of +6.64%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 50 | 4% |
Analysts Target Price | 49.4 | 2.7% |
ValueRay Target Price | 51.3 | 6.6% |